Based on our previous study on the use of metformin in HCC and the proteomics results in this study, we determined the induction of EMT in liver cancer cells by bFGF, and we confirmed that metformin could reverse the bFGF-induced EMT in HepG2 and Huh7 cells. This evidence concerns the gene FGF2 and hepatocellular carcinoma.